Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested
for recurrent (returning) malignant gliomas. An investigational drug is one that has not been
approved by the U.S. Food and Drug Administration (FDA). It belongs to a new class of drugs
called "histone deacetylase inhibitors." Histones are proteins located in the nucleus of
cells that bind to DNA, the chemical that makes up genes. These proteins help control which
genes are turned "on" and "off." Studies have shown that drugs like panobinostat (LBH589) may
lead to tumor cell death.